ACACB
Summary: Acetyl-CoA carboxylase (ACC) is a complex multifunctional enzyme system. ACC is a biotin-containing enzyme which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the rate-limiting step in fatty acid synthesis. ACC-beta is thought to control fatty acid oxidation by means of the ability of malonyl-CoA to inhibit carnitine-palmitoyl-CoA transferase I, the rate-limiting step in fatty acid uptake and oxidation by mitochondria. ACC-beta may be involved in the regulation of fatty acid oxidation, rather than fatty acid biosynthesis. There is evidence for the presence of two ACC-beta isoforms. [provided by RefSeq, Jul 2008].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| acetyl-CoA carboxylase beta | MIM:601557 | Ensembl:ENSG00000076555 | HGNC:HGNC:85 | PA24422 | 12q24.11 |
GO terms in ACACB
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IDA | GO:0003989 | acetyl-CoA carboxylase activity |
| MF | TAS | GO:0003989 | acetyl-CoA carboxylase activity |
| MF | IEA | GO:0004075 | biotin carboxylase activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0005524 | ATP binding |
| MF | IEA | GO:0009374 | biotin binding |
| MF | IPI | GO:0042802 | identical protein binding |
| MF | IEA | GO:0046872 | metal ion binding |
| BP | IDA | GO:0006084 | acetyl-CoA metabolic process |
| BP | IEA | GO:0006633 | fatty acid biosynthetic process |
| BP | TAS | GO:0006853 | carnitine shuttle |
| BP | IEA | GO:0010629 | negative regulation of gene expression |
| BP | IEA | GO:0010884 | positive regulation of lipid storage |
| BP | IEA | GO:0010906 | regulation of glucose metabolic process |
| BP | IEA | GO:0014070 | response to organic cyclic compound |
| BP | TAS | GO:0031325 | positive regulation of cellular metabolic process |
| BP | IEA | GO:0031667 | response to nutrient levels |
| BP | IEA | GO:0031999 | negative regulation of fatty acid beta-oxidation |
| BP | IEA | GO:0042493 | response to drug |
| BP | IEA | GO:0043086 | negative regulation of catalytic activity |
| BP | TAS | GO:0045540 | regulation of cholesterol biosynthetic process |
| BP | IDA | GO:0051289 | protein homotetramerization |
| BP | IEA | GO:0060421 | positive regulation of heart growth |
| BP | IEA | GO:0097009 | energy homeostasis |
| BP | IEA | GO:2001295 | malonyl-CoA biosynthetic process |
| CC | IDA | GO:0005634 | nucleus |
| CC | IDA | GO:0005739 | mitochondrion |
| CC | TAS | GO:0005741 | mitochondrial outer membrane |
| CC | TAS | GO:0005829 | cytosol |
| CC | IEA | GO:0012505 | endomembrane system |
Gene expression in normal tissue: ACACB
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in ACACB
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| pharmgkb | PA165948566 | Metformin Pathway, Pharmacodynamic |
| humancyc | PWY-5966-1 | fatty acid biosynthesis initiation |
| humancyc | PWY0-1264 | biotin-carboxyl carrier protein assembly |
| netpath | Pathway_Leptin | Leptin |
| kegg | hsa00061 | Fatty acid biosynthesis - Homo sapiens (human) |
| kegg | hsa00620 | Pyruvate metabolism - Homo sapiens (human) |
| kegg | hsa00640 | Propanoate metabolism - Homo sapiens (human) |
| kegg | hsa04152 | AMPK signaling pathway - Homo sapiens (human) |
| kegg | hsa04910 | Insulin signaling pathway - Homo sapiens (human) |
| kegg | hsa04920 | Adipocytokine signaling pathway - Homo sapiens (human) |
| kegg | hsa04922 | Glucagon signaling pathway - Homo sapiens (human) |
| kegg | hsa04931 | Insulin resistance - Homo sapiens (human) |
| wikipathways | WP1403 | AMP-activated Protein Kinase (AMPK) Signaling |
| wikipathways | WP2034 | Leptin signaling pathway |
| wikipathways | WP2380 | Brain-Derived Neurotrophic Factor (BDNF) signaling pathway |
| wikipathways | WP2593 | JAK-STAT |
| wikipathways | WP2706 | Activation of gene expression by SREBF (SREBP) |
| wikipathways | WP357 | Fatty Acid Biosynthesis |
| wikipathways | WP3888 | VEGFA-VEGFR2 Signaling Pathway |
| wikipathways | WP4010 | Liver steatosis AOP |
| wikipathways | WP4018 | Pathways in clear cell renal cell carcinoma |
| wikipathways | WP4206 | Hereditary Leiomyomatosis and Renal Cell Carcinoma Pathway |
| reactome | R-HSA-1430728 | Metabolism |
| reactome | R-HSA-163685 | Integration of energy metabolism |
| reactome | R-HSA-163765 | ChREBP activates metabolic gene expression |
| reactome | R-HSA-1655829 | Regulation of cholesterol biosynthesis by SREBP (SREBF) |
| reactome | R-HSA-196780 | Biotin transport and metabolism |
| reactome | R-HSA-196849 | Metabolism of water-soluble vitamins and cofactors |
| reactome | R-HSA-196854 | Metabolism of vitamins and cofactors |
| reactome | R-HSA-200425 | Import of palmitoyl-CoA into the mitochondrial matrix |
| reactome | R-HSA-2426168 | Activation of gene expression by SREBF (SREBP) |
| reactome | R-HSA-556833 | Metabolism of lipids |
| reactome | R-HSA-8957322 | Metabolism of steroids |
| reactome | R-HSA-8978868 | Fatty acid metabolism |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD188 | Piperlongumine | 3 |
| iGMDRD399 | Selumetinib | 2 |
| iGMDRD74 | Idarubicin | 1 |
| iGMDRD577 | BIX01294 | 4 |
| iGMDRD562 | Navitoclax | 4 |
| iGMDRD60 | Quinoclamine | 2 |
| iGMDRD640 | CAY10618 | 3 |
| iGMDRD64 | Parbendazole | 4 |
| iGMDRD451 | Serdemetan | 2 |
| iGMDRD138 | PX 12 | 1 |
| iGMDRD255 | SB225002 | 2 |
| iGMDRD171 | Pemetrexed | 1 |
| iGMDRD782 | DC-45-A2 | 4 |
| iGMDRD441 | TW 37 | 2 |
| iGMDRD885 | Compound 110 | 2 |
| iGMDRD187 | BRD9876 | 1 |
| iGMDRD446 | LY 2183240 | 5 |
| iGMDRD71 | Sparfosic acid | 2 |
| iGMDRD639 | YK 4-279 | 1 |
| iGMDRD193 | Fqi1 | 3 |
| iGMDRD61 | Kinetin riboside | 4 |
| iGMDRD280 | CYTOCHALASIN B | 4 |
| iGMDRD394 | BX-795 | 4 |
| iGMDRD466 | Chaetocin | 3 |
| iGMDRD634 | SCHEMBL2608041 | 2 |
| iGMDRD554 | CHEMBL1434137 | 2 |
| iGMDRD599 | Salermide | 2 |
| iGMDRD387 | CHIR-99021 | 1 |
| iGMDRD229 | B02 | 3 |
| iGMDRD427 | ABT737 | 1 |
| iGMDRD781 | Sirolimus | 2 |
| iGMDRD82 | Quiflapon | 2 |
| iGMDRD322 | FK 866 | 3 |
| iGMDRD121 | GMX1778 | 6 |
| iGMDRD158 | NSC141540 | 3 |
| iGMDRD6 | AM-580 | 3 |
| iGMDRD289 | Parthenolide | 3 |
| iGMDRD434 | BMS-536924 | 2 |
| iGMDRD231 | Importazole | 3 |
| iGMDRD85 | Ursolic acid | 3 |
| iGMDRD901 | ELCPK | 1 |
| iGMDRD177 | Teniposide | 2 |
| iGMDRD84 | Lovastatin acid | 4 |
| iGMDRD486 | Tosedostat | 1 |
| iGMDRD512 | nutlin 3 | 1 |
| iGMDRD532 | Olaparib | 2 |
| iGMDRD560 | MK-2206 | 3 |
| iGMDRD345 | Compound 10b [PMID: 11504634] | 2 |
| iGMDRD299 | ICL 670 | 1 |
| iGMDRD79 | Gemcitabine | 7 |
Gene in drug-gene network: Network Plot

Gene-drug targets distribution
Gene Structure: PDB
Models in ACACB

